Antineoplastic effects of rosiglitazone and PPARγ transactivation in neuroblastoma cells
Open Access
- 12 September 2006
- journal article
- Published by Springer Nature in British Journal of Cancer
- Vol. 95 (7) , 879-888
Abstract
Neuroblastoma (NB) is the most common extracranial solid tumour in infants. Unfortunately, most children present with advanced disease and have a poor prognosis. In the present study, we evaluated the role of the peroxisome proliferator-activated receptor γ (PPARγ) agonist rosiglitazone (RGZ) in two NB cell lines (SK-N-AS and SH-SY5Y), which express PPARγ. Rosiglitazone decreased cell proliferation and viability to a greater extent in SK-N-AS than in SH-SY5Y. Furthermore, 20 μM RGZ significantly inhibited cell adhesion, invasiveness and apoptosis in SK-N-AS, but not in SH-SY5Y. Because of the different response of SK-N-AS and SH-SY5Y cells to RGZ, the function of PPARγ as a transcriptional activator was assessed. Noticeably, transient transcription experiments with a PPARγ responsive element showed that RGZ induced a three-fold increase of the reporter activity in SK-N-AS, whereas no effect was observed in SH-SY5Y. The different PPARγ activity may be likely due to the markedly lower amount of phopshorylated (i.e. inactive) protein observed in SK-N-AS. To our knowledge, this is the first demonstration that the differential response of NB cells to RGZ may be related to differences in PPARγ transactivation. This finding indicates that PPARγ activity may be useful to select those patients, for whom PPARγ agonists may have a beneficial therapeutic effect.Keywords
This publication has 49 references indexed in Scilit:
- Ligands for the peroxisome proliferator-activated receptor-γ have inhibitory effects on growth of human neuroblastoma cells in vitroToxicology, 2005
- Mutational analysis of PPARG as a candidate tumour suppressor gene in enteropancreatic endocrine tumoursClinical Endocrinology, 2005
- Antidiabetic thiazolidinediones inhibit invasiveness of pancreatic cancer cells via PPARγ independent mechanismsGut, 2004
- Antineoplastic effects of peroxisome proliferatoractivated receptor γ agonistsThe Lancet Oncology, 2004
- The Synthetic Ligand of Peroxisome Proliferator-Activated Receptor-γ Ciglitazone Affects Human Glioblastoma Cell LinesThe Journal of Pharmacology and Experimental Therapeutics, 2004
- Peroxisome Proliferator-activated Receptor γ-mediated DifferentiationJournal of Biological Chemistry, 2003
- Effects of retinoic acid on proliferation, apoptosis, cytotoxicity, migration, and invasion of neuroblastoma cellsMedical and Pediatric Oncology, 2003
- A Phase II Study of Troglitazone, an Activator of the PPAR?? Receptor, in Patients with Chemotherapy-Resistant Metastatic Colorectal CancerThe Cancer Journal, 2002
- Modulating nuclear receptor function: may the phos be with youJournal of Clinical Investigation, 1999
- Knockout of α6β1-integrin expression reverses the transformed phenotype of hepatocarcinoma cellsGastroenterology, 1998